These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15180770)

  • 21. Fixed drug eruption to rofecoxib.
    Nedorost ST; Florentino FT; Gilliam AC
    Cutis; 2002 Aug; 70(2):125-6. PubMed ID: 12234159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety of rofecoxib.
    Burnier M
    Expert Opin Drug Saf; 2005 May; 4(3):491-9. PubMed ID: 15934855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 25. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 28. [Gastrointestinal complications under NSAID treatment in the doctor's office].
    Hollenz M; Labenz J
    MMW Fortschr Med; 2004 Dec; 146(49):42, 44. PubMed ID: 15646716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rofecoxib--a recall with implications].
    Hansen PR
    Ugeskr Laeger; 2004 Dec; 166(50):4573. PubMed ID: 15633542
    [No Abstract]   [Full Text] [Related]  

  • 30. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
    Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
    Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NSAID-sensitive patients tolerate rofecoxib.
    Valero A; Baltasar M; Enrique E; Pau L; Dordal MT; Cisteró A; Martí E; Picado C
    Allergy; 2002 Dec; 57(12):1214-5. PubMed ID: 12464059
    [No Abstract]   [Full Text] [Related]  

  • 34. Withdrawal syndrome.
    Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
    [No Abstract]   [Full Text] [Related]  

  • 35. [Rofecoxib (Vioxx) has been withdrawn, what next?].
    Idänpään-Heikkilä JE; Klaukka T
    Duodecim; 2004; 120(21):2489-90. PubMed ID: 15631403
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of living-related kidney transplantation in Bartter's syndrome.
    Kim JY; Kim GA; Song JH; Lee SW; Han JY; Lee JS; Kim MJ
    Yonsei Med J; 2000 Oct; 41(5):662-5. PubMed ID: 11079628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 39. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 40. Vioxx and Merck: a preventable situation?
    Torg J
    Orthopedics; 2005 Mar; 28(3):248, 250. PubMed ID: 15790082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.